The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Tsunoda T, Oyama Y, Miyamoto R, Ito T, Akashi T, Tsuchiya K, Ikeda M

Regorafenib Induced Interstitial Pneumonia in a Patient With Refractory Rectal Cancer.

Respirology case reports 2025 Aug;13;e70286 — 2025 Aug — e70286

Kotani K, Enomoto M, Okada M, Yoshida K, Motoyama H, Fujii H, Hagihara A, Uchida-Kobayashi S, Morikawa H, Murakami Y, Tamori A, Kawada N

Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.

Clinical journal of gastroenterology 2019 Apr 24;; — 2019 Apr 24